Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
AstraZeneca speeds R&D decision making with cutting-edge life sciences technology
Facebook
Facebook
Twitter
Twitter
LinkedIn
LinkedIn
Email
Email
0 Comments
Comments
“Oncology is critical for pharma, as is evidenced by the World Health Organization’s projection that an estimated 13.1 million people will die from cancer in 2030, up from the 7.6 million who died in 2008,” said Wendy Hamilton, senior vice president at Thomson Reuters. “The ability of drug companies to quickly find the most relevant research data and clinical information for their oncology studies, in meetings, on the move or at the bench, will allow them to make faster business decisions and focus on areas where there is unmet need.”
0 Comments
View Comments
- People:
- Wendy Hamilton
- Places:
- PHILADELPHIA, PA
Press Release
Author's page
Related Content
Comments